Navigation Links
HORIZONS AMI trial data will help set guidelines
Date:10/24/2007

WASHINGTON, DC OCTOBER 24, 2007 Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation (CRF), show that the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduces net adverse clinical events by 24 percent compared to the standard treatment, and significantly reduces major bleeding that occurs after angioplasty by 40 percent.

Results of the HORIZONS AMI trial, sponsored by the Cardiovascular Research Foundation, were measured at 30 days; the patients will be observed for five years to collect long-term data.

This is a landmark trial, which will help establish the guidelines for drug and stent therapy during primary angioplasty in patients with heart attacks for many years to come, said Gregg W. Stone, MD, Chairman of the Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center.

Usually, angioplasty is associated with an excess of bleeding in heart attack patients, Dr. Stone said. In the first phase of the HORIZONS AMI trial, we sought to determine whether using bivalirudin instead of heparin and glycoprotein IIb/IIIa inhibitors in patients with a heart attack after angioplasty reduces this high rate of bleeding and improves survival, as it does in stable coronary artery disease.

In addition, while previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the most dangerous form of heart attack (ST-elevation myocardial infarction).

The HORIZONS AMI trial enrolled over 3600 patients presenting to hospitals in 11 countries with a heart attack. More than 120 national and international interventional cardiology centers are participating in the trial. Patients undergoing angioplasty were randomly assigned to receive either the standard anticoagulant regimen of unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor or bivalirudin alone. The patients are to be followed for five years.

At 30 days, net adverse clinical events a combination of major bleeding or major adverse cardiac event were 12.1% in patients receiving heparin and GP IIb/IIIa inhibitors, and 9.2% in patients receiving bivalirudin alone. And when considered by itself, major bleeding was 8.3% in patients on combination drug therapy, vs. 4.9% in patients on bivalirudin alone.

In an important finding, cardiac deaths at 30 days were significantly higher in patients on heparin and GP IIb/IIIa inhibitors (2.9%) than those on bivalirudin alone (1.8%). Other important endpoints, such as second heart attacks and strokes, occurred with nearly identical frequency with bivalirudin and standard therapy.

This study determines that bivalirudin use is safer than previous standard anticoagulant therapy, without causing excess bleeding in these acutely ill patients with a heart attack undergoing angioplasty, which may translate into lower mortality, said Roxana Mehran, MD, Medical Director of the Data Coordinating and Analysis Center at CRF stated. She and her team conducted this study under an Investigational Device Exemption (IDE) from the Food and Drug Administration.

Comparison of Drug-Eluting Stents to Bare-Metal Stents Underway

Patients enrolled in the HORIZONS AMI trial were also randomly assigned to receive either Taxus drug-eluting stents or a bare-metal stent. Data on this portion of the study also a landmark comparison of drug-eluting stents to bare-metal stents will be available next year.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: